CD1d is a specific ligand for the invariant Valpha24Vbeta11-natural killer T (iNKT) cells that play an important role in placental development during early human pregnancy. The localization and regulation of placental CD1d expression remain unclear. Immunohistochemistry of human early gestational placentas revealed CD1d was present in villous and extravillous trophoblast (EVT) but not in syncytiotrophoblast or decidual cells. CD1d immunoreactivity in EVT cells decreased with EVT differentiation. Flow cytometry of primary cultured human trophoblast cells confirmed cell-surface expression of CD1d decreased with time in culture. These changes in CD1d expression occur at the level of transcription. TGF-beta1 secreted from the cultured EVT cells accumulated with time in culture and directly suppressed CD1d expression, as evidenced by monoclonal antibody neutralization of TGF-beta1 effects. Thus, trophoblast differentiation is characterized by TGF-beta1-mediated decreases in trophoblast cell CD1d expression. This effect may support appropriate activation of decidual iNKT cells at the maternal-fetal interface.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2008.04.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function.
Cancer Immunol Res
January 2025
Baylor College of Medicine, Houston, TX, United States.
Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that employs a guide RNA (gRNA) library targeting 1,118 immune-related genes. Unmodified NKTs and NKTs expressing a GD2-specific chimeric antigen receptor (GD2.
View Article and Find Full Text PDFBioinformatics-based analysis of the role of immune-related genes in acute rejection after kidney transplantation and renal cancer development.
Medicine (Baltimore)
November 2024
Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Acute rejection (AR) is a common complication in the early stage after kidney transplantation. Some studies have shown that the occurrence of AR after kidney transplantation may further affect the development of tumors, and both AR and tumor development are related to immune cells and immune genes, so it is particularly important to diagnose the occurrence of AR at an early stage and to analyze the correlation between AR and tumors. In this study, we applied bioinformatics techniques for differential expression analysis and weighted gene co-expression network analysis analysis of AR patients to obtain differentially expressed genes and modular genes significantly associated with AR, respectively, so as to obtain their intersecting genes with immune-related genes; 21 intersecting genes were screened by lasso regression and Boruta algorithm to obtain the genes, and finally, the feature genes that were significantly associated with the dependent variable were further obtained by single-factor and multi-factor logistic regression.
View Article and Find Full Text PDFThe α glycolipid rules the NKT cell TCR.
J Exp Med
February 2025
La Jolla Institute for Immunology, La Jolla, CA, USA.
In this issue of JEM, Hosono et al. (https://doi.org/10.
View Article and Find Full Text PDFIdentification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells.
J Exp Med
February 2025
Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Article Synopsis
- Invariant natural killer T (iNKT) cells are unique T cells that recognize lipid antigens through a molecule called CD1d, with α-galactosylceramide (α-GalCer) being the strongest known antigen.
- Researchers created a specialized system using supercritical fluid chromatography tandem mass spectrometry (SFC/MS/MS) to separate and identify different forms of hexosylceramide.
- Their findings revealed that α-GalCer, previously not found in mammals, is present in various biological fluids, representing the first identification of this potent antigen in mammalian systems.
CAR-iNKT cell therapy: mechanisms, advantages, and challenges.
Curr Res Transl Med
December 2024
Beijing Rongai Biotechnology Co., Ltd, 1st Floor, Building 29, No. 5 Kechuang East 2nd Street, Tongzhou District, Beijing 101100, China. Electronic address:
Article Synopsis
- CAR T-cell therapy has shown significant promise in treating blood cancers like B-ALL and multiple myeloma, leading to new approvals of CAR-T products that benefit many patients.
- However, its use in solid tumors is limited due to challenges like tumor microenvironments, variable antigen expression, and side effects.
- Invariant natural killer T (iNKT) cells, with their unique properties, are being investigated as a complement to CAR-T therapy, and researchers are exploring CAR technology to enhance iNKT cells’ effectiveness in targeting solid tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!